Observational studyAnnals of medicine2025

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.

I Gentile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.